Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bupropion for the Prevention of Postpartum Smoking Relapse
Sponsor: University of Minnesota
Summary
This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks post-randomization). All participants will complete the same data collection procedures (e.g., biological sample collection for hormone and cotinine analysis and completion of validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52 post-randomization.
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-01-01
Completion Date
2026-07-31
Last Updated
2026-01-07
Healthy Volunteers
Yes
Conditions
Interventions
Bupropion Extended Release Oral Tablet
12 weeks postpartum of blinded study medication
Placebo oral tablet
12 weeks postpartum of blinded placebo
Locations (1)
University of Minnesota
Minneapolis, Minnesota, United States